600479 千金药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.97810.4299.51213.91113.853
总资产报酬率 ROA (%)3.6316.0154.9986.8826.958
投入资产回报率 ROIC (%)4.9198.6507.76710.71410.758

边际利润分析
销售毛利率 (%)49.68048.77646.37946.11743.127
营业利润率 (%)12.20512.0499.15012.16111.034
息税前利润/营业总收入 (%)12.21511.5068.49210.96010.990
净利润/营业总收入 (%)10.42110.3528.33710.3999.615

收益指标分析
经营活动净收益/利润总额(%)90.99887.32893.15195.76992.331
价值变动净收益/利润总额(%)5.50110.7104.8363.7364.408
营业外收支净额/利润总额(%)-0.658-0.4940.953-0.3300.351

偿债能力分析
流动比率 (X)1.4521.4512.0482.2792.070
速动比率 (X)1.1331.1221.6831.9331.717
资产负债率 (%)33.01132.50631.10335.28339.217
带息债务/全部投入资本 (%)14.36214.67013.00717.37921.608
股东权益/带息债务 (%)574.720559.046646.666456.082345.886
股东权益/负债合计 (%)183.154187.683173.748144.817121.975
利息保障倍数 (X)135.488-23.745-11.391-9.440-132.889

营运能力分析
应收账款周转天数 (天)31.97026.76925.05423.97121.422
存货周转天数 (天)91.49294.53994.33899.65390.145